Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
SHR-5421 in Multiple Myeloma: NCT07652281 Clinical Landscape Report 2026
16 September 2026
NCT07652281 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Guselkumab in Arthritis, Psoriatic: NCT07654751 Clinical Landscape Report 2026
16 September 2026
NCT07654751 clinical landscape for Arthritis, Psoriatic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
NK Cell (Sinorda Bio) in Hepatocellular Carcinoma: NCT07657416 Clinical Landscape Report 2026
16 September 2026
NCT07657416 clinical landscape for Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tislelizumab in Breast Cancer: CTRI/2026/06/113041 Clinical Landscape Report 2026
16 September 2026
CTRI/2026/06/113041 clinical landscape for Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Indocyanine Green in Metastatic osteosarcoma: NCT07658768 Clinical Landscape Report 2026
16 September 2026
NCT07658768 clinical landscape for Metastatic osteosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lutetium-177 EBRGD in Glioblastoma, IDH-Wildtype: NCT07655869 Clinical Landscape Report 2026
16 September 2026
NCT07655869 clinical landscape for Glioblastoma, IDH-Wildtype: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Adalimumab biosimilar(Jiangsu Chia-tai Tianqing Pharmaceutical Co. Ltd.) in Plaque psoriasis: NCT07663331 Clinical Landscape Report 2026
16 September 2026
NCT07663331 clinical landscape for Plaque psoriasis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ruxolitinib in Dermatitis, Atopic: NCT07661979 Clinical Landscape Report 2026
16 September 2026
NCT07661979 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cryptigens in Ovarian Cancer: NCT07665515 Clinical Landscape Report 2026
16 September 2026
NCT07665515 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ocrelizumab in Multiple Sclerosis: NCT07667322 Clinical Landscape Report 2026
16 September 2026
NCT07667322 clinical landscape for Multiple Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lidocaine in Uterine Cervical Cancer: PACTR202606770457238 Clinical Landscape Report 2026
16 September 2026
PACTR202606770457238 clinical landscape for Uterine Cervical Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
GT737 in Relapsing acute myeloid leukemia: NCT07676006 Clinical Landscape Report 2026
16 September 2026
NCT07676006 clinical landscape for Relapsing acute myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…